<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="db2757aa-d8c7-4114-b4bb-5eeec0df762f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ARSENIC TRIOXIDE INJECTION safely and effectively. See full prescribing information for ARSENIC TRIOXIDE INJECTION.<br/>ARSENIC TRIOXIDE injection, for intravenous use <br/>Initial U.S. Approval: 2000</title>
   <effectiveTime value="20250512"/>
   <setId root="ae5cae02-ca57-4da5-8940-81253fdb8679"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="156861945" root="1.3.6.1.4.1.519.1"/>
            <name>Zydus Pharmaceuticals USA Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="650348852" root="1.3.6.1.4.1.519.1"/>
                        <name>Zydus Lifesciences Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70710-1895" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70710-1895" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="51d280ad-0f35-48e1-b660-3cdf604a8f28"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250512"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70710-1895" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Arsenic trioxide</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Arsenic trioxide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="S7V92P67HO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARSENIC TRIOXIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="C96613F5AV" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ARSENIC CATION (3+)</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70710-1895-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70710-1895-6" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230228"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA206228" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230228"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID564">
               <id root="82212a57-cd3c-4882-ab4d-be4a9e3f0029"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>Boxed Warning</title>
               <text>
                  <paragraph ID="ID565">
                     <content styleCode="bold">WARNING: DIFFERENTIATION SYNDROME, CARDIAC CONDUCTION ABNORMALITIES, and ENCEPHALOPATHY INCLUDING WERNICKE'S</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Differentiation Syndrome: Patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide have experienced differentiation syndrome, which may be life-threatening or fatal. Signs and symptoms may include unexplained fever, dyspnea, hypoxia, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, weight gain, peripheral edema, hypotension, renal insufficiency, hepatopathy, and multi-organ dysfunction, in the presence or absence of leukocytosis. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. Temporarily withhold arsenic trioxide <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID579">2.3</linkHtml>), Warnings and Precautions (<linkHtml href="#ID597">5.1</linkHtml>)].</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cardiac Conduction Abnormalities: Arsenic trioixde can cause QTc interval prolongation, complete atrioventricular block and torsade de pointes, which can be fatal. Before administering arsenic trioxide, assess the QTc interval, correct electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide to patients with a ventricular arrhythmia or prolonged QTc interval. Withhold arsenic trioxide until resolution and resume at reduced dose for QTc prolongation <content styleCode="italics">[see Dosage and Administration</content> <content styleCode="italics">(<linkHtml href="#ID579">2.3</linkHtml>), Warnings and Precautions (<linkHtml href="#ID599">5.2</linkHtml>)].</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Encephalopathy: Serious encephalopathy, including Wernicke's, has occurred with arsenic trioxide. Wernicke's is a neurologic emergency. Consider testing thiamine levels in patients at risk for thiamine deficiency. Administer parenteral thiamine in patients with or at risk for thiamine deficiency. Monitor patients for neurological symptoms and nutritional status while receiving arsenic trioxide. If Wernicke's encephalopathy is suspected, immediately interrupt arsenic trioxide and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID601">5.3</linkHtml>)].</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID567">
                           <content styleCode="bold">WARNING: DIFFERENTIATION SYNDROME, CARDIAC CONDUCTION ABNORMALITIES, and ENCEPHALOPATHY INCLUDING WERNICKE'S</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID568" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide have experienced symptoms of differentiation syndrome, which may be life-threatening or fatal. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. Temporarily withhold arsenic trioxide. (<linkHtml href="#ID579">2.3</linkHtml>, <linkHtml href="#ID597">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Arsenic trioxide can cause QTc interval prolongation, complete atrioventricular block and torsade de pointes, which can be fatal. Before administering arsenic trioxide, assess the QTc interval, correct electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide to patients with ventricular arrhythmia or prolonged QTc interval. Withhold arsenic trioxide until resolution and resume at reduced dose for QTc prolongation. (<linkHtml href="#ID579">2.3</linkHtml>, <linkHtml href="#ID599">5.2</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Serious encephalopathy, including Wernicke's, has occurred with arsenic trioxide. If Wernicke's encephalopathy is suspected, immediately interrupt arsenic trioxide and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize. (<linkHtml href="#ID601">5.3</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID569">
               <id root="b52449cd-1187-4cc0-85e3-cec7bc44109c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID573">Arsenic trioxide injection is an arsenical indicated:</paragraph>
                        <list listType="unordered" ID="ID574" styleCode="Disc">
                           <item>In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. (<linkHtml href="#ID677">1.1</linkHtml>)</item>
                           <item>For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. (<linkHtml href="#ID570">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID677">
                     <id root="adfe79ee-8fc6-4013-abed-009c7b27efaa"/>
                     <title>1.1 Newly-Diagnosed Low-Risk APL</title>
                     <text>
                        <paragraph ID="ID678">Arsenic trioxide injection is indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID570">
                     <id root="26e51fbf-a776-4655-a0cf-051bb1327a4c"/>
                     <title>1.2 Relapsed or Refractory APL</title>
                     <text>
                        <paragraph ID="ID571">Arsenic trioxide injection is indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID575">
               <id root="f726540d-d492-4458-b9a9-8f7dd78c9a1e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID675">
                           <content styleCode="underline">Newly-diagnosed low-risk APL:</content>
                        </paragraph>
                        <list listType="unordered" ID="ID676" styleCode="Disc">
                           <item>Induction: Administer 0.15 mg/kg/day intravenously daily in combination with tretinoin until bone marrow remission. Do not exceed 60 days. (<linkHtml href="#ID679">2.1</linkHtml>)</item>
                           <item>Consolidation: Administer 0.15 mg/kg/day intravenously daily for 5 days per week during weeks 1-4 of each 8-week cycle for a total of 4 cycles in combination with tretinoin. (<linkHtml href="#ID679">2.1</linkHtml>)</item>
                        </list>
                        <paragraph ID="ID586">
                           <content styleCode="underline">Relapsed or refractory APL:</content>
                        </paragraph>
                        <list listType="unordered" ID="ID587" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Induction:</content> Administer 0.15 mg/kg/day intravenously daily until bone marrow remission. Do not exceed 60 days. (<linkHtml href="#ID576">2.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Consolidation: </content> Administer 0.15 mg/kg/day intravenously daily for 25 doses over a period of up to 5 weeks. (<linkHtml href="#ID576">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID679">
                     <id root="7c0973a3-a368-4481-8c9b-a531959483e8"/>
                     <title>2.1 Recommended Dosage for Newly-Diagnosed Low-Risk Acute Promyelocytic Leukemia (APL)</title>
                     <text>
                        <paragraph ID="ID680">A treatment course for patients with newly-diagnosed low-risk APL consists of 1 induction cycle and 4 consolidation cycles.</paragraph>
                        <list listType="unordered" ID="ID681" styleCode="Disc">
                           <item>For the induction cycle, the recommended dosage of arsenic trioxide is 0.15 mg/kg/day intravenously daily in combination with tretinoin until bone marrow remission but not to exceed 60 days (see Table 1).</item>
                           <item>For the consolidation cycles, the recommended dosage of arsenic trioxide is 0.15 mg/kg/day intravenously daily 5 days per week during weeks 1 to 4 of each 8-week cycle for a total of 4 cycles in combination with tretinoin (see Table 1). Omit tretinoin during weeks 5-6 of the fourth cycle of consolidation.</item>
                        </list>
                        <table ID="ID682" width="638" styleCode="Noautorules">
                           <caption>  Table 1Recommended Dosage of arsenic trioxide in Combination with Tretinoin Induction (1 cycle) </caption>
                           <col width="319"/>
                           <col width="319"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left"> Arsenic trioxide 0.15 mg/kg once daily intravenously<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left"> until marrow remission but not to exceed 60 days<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Tretinoin<sup>a</sup> 22.5 mg/m<sup>2</sup> twice daily orally<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> until marrow remission but not to exceed 60 days<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID683">
                           <content styleCode="bold">Consolidation (4 cycles)</content>
                        </paragraph>
                        <table ID="ID684" width="638" styleCode="Noautorules">
                           <col width="102"/>
                           <col width="67"/>
                           <col width="67"/>
                           <col width="67"/>
                           <col width="67"/>
                           <col width="67"/>
                           <col width="67"/>
                           <col width="67"/>
                           <col width="67"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="9">
                                    <paragraph styleCode="Footnote">a Rounded to the nearest 10 mg increment</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="9">
                                    <paragraph styleCode="Footnote">b Omitted during the 4th cycle of consolidation</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Week</content>
                                    <br/>
                                    <content styleCode="bold"> 1</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Week</content>
                                    <br/> 2<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Week</content>
                                    <br/> 3<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Week</content>
                                    <br/> 4<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Week</content>
                                    <br/> 5<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Week</content>
                                    <br/> 6<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Week</content>
                                    <br/> 7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Week</content>
                                    <br/> 8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Arsenic trioxide 0.15 mg/kg once daily intravenously<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> Days 1 to 5<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> Days 1 to 5<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> Days 1 to 5<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> Days 1 to 5<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> --<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> --<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> --<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> --<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Tretinoin<sup>a </sup>22.5 mg/m<sup>2</sup> twice daily orally<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> Days 1to7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> Days 1to7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> --<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> --<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> Days<sup>b</sup> 1to7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> Days<sup>b</sup> 1to7<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> --<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> --<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID685">Differentiation syndrome prophylaxis consisting of prednisone 0.5 mg/kg daily from day 1 until the end of induction cycle with arsenic trioxide and tretinoin is recommended.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID576">
                     <id root="a58d4657-221f-48e9-8709-3bc2abb71437"/>
                     <title>2.2 Recommended Dosage for Relapsed or Refractory APL</title>
                     <text>
                        <paragraph ID="ID577">A treatment course for patients with relapsed or refractory APL consists of 1 induction cycle and 1 consolidation cycle <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID658">14.2</linkHtml>)]</content>.</paragraph>
                        <list listType="unordered" ID="ID578" styleCode="Disc">
                           <item>For the induction cycle, the recommended dosage of arsenic trioxide is 0.15 mg/kg/day intravenously daily until bone marrow remission or up to a maximum of 60 days.</item>
                           <item>For the consolidation cycle, the recommended dosage of arsenic trioxide is 0.15 mg/kg/day intravenously daily for 25 doses over a period of up to 5 weeks. Begin consolidation 3 to 6 weeks after completion of induction cycle.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID579">
                     <id root="d7cc3197-1285-42a3-9787-ac0dbcb1cf53"/>
                     <title>2.3 Monitoring and Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph ID="ID580">During induction, monitor coagulation studies, blood counts, and chemistries at least 2-3 times per week through recovery. During consolidation, monitor coagulation studies, blood counts, and chemistries at least weekly.</paragraph>
                        <paragraph>Table 2 shows the dosage modifications for adverse reactions due to arsenic trioxide when used alone or in combination with tretinoin.</paragraph>
                        <table ID="ID581" width="100%" styleCode="Noautorules">
                           <caption>  Table 2 Dosage Modifications for Adverse Reactions of Arsenic Trioxide </caption>
                           <col width="34%"/>
                           <col width="65%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Toprule Botrule Rrule" align="left">  <content styleCode="bold"> Adverse Reaction</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dosage Modification</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Differentiation syndrome, defined by the presence of 2 or more of the following:<br/> -   Unexplained fever<br/> -   Dyspnea<br/> -   Pleural and/or pericardial effusion<br/> -   Pulmonary infiltrates<br/> -   Renal failure<br/> -   Hypotension<br/> -   Weight gain greater than 5 kg <br/>
                                    <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID597">5.1</linkHtml>)]</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Temporarily withhold arsenic trioxide. Consider holding tretinoin if symptoms are severe.  </item>
                                       <item>Administer dexamethasone 10 mg intravenously every 12 hours until the resolution of signs and symptoms for a minimum of 3 days.</item>
                                       <item>Resume treatment when the clinical condition improves and reduce the dose of the withheld drug(s) by 50%.</item>
                                       <item>Increase the dose of the withheld drug(s) to the recommended dosage after one week in the absence of recurrence of symptoms of differentiation syndrome.</item>
                                       <item>If symptoms re-appear, decrease arsenic trioxide and/or</item>
                                    </list>
 tretinoin to the previous dose.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> QTc (Framingham formula) Prolongation greater than 450 msec for men or greater than 460 msec for women:<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#ID599">5.2</linkHtml>)]</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Withhold arsenic trioxide and any medication known to prolong the QTc interval.</item>
                                       <item>Correct electrolyte abnormalities.</item>
                                       <item>After the QTc normalizes and electrolyte abnormalities are corrected, resume treatment with arsenic trioxide at a 50% reduced dose (0.075 mg/kg/day daily) for one week after resolution.</item>
                                       <item>If the 50% reduced dose is tolerated for one week (in the absence of QTc prolongation), increase the dose of arsenic trioxide to 0.11 mg/kg/day daily for the next week [see Dosage and Administration (<linkHtml href="#ID576">2.1</linkHtml>)].</item>
                                       <item>The dose of arsenic trioxide can be increased to 0.15 mg/kg/day in the absence of QTc prolongation during that 14-day dose-escalation period. </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hepatotoxicity, defined by 1 or more of the following:<br/> -   Total bilirubin (TB) greater than 3 times the upper limit of normal (ULN)<br/> -   Aspartate aminotransferase (AST) greater than 5 times the ULN<br/> -   Alkaline phosphatase (AP) greater than 5 times the ULN<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID603">5.4</linkHtml>)]</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Withhold arsenic trioxide and/or tretinoin.</item>
                                       <item>Resume treatment at a 50% reduced dose of the withheld drug(s) when TB is less than 1.5 times the ULN and AP/AST are less than 3 times the ULN.</item>
                                       <item>Increase the dose of the withheld drug(s) back to the recommended dosage after one week on the reduced dose in the absence of worsening of hepatotoxicity.</item>
                                       <item>Discontinue the withheld drug(s) permanently if hepatotoxicity recurs. </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Other severe or life-threatening (grade 3-4) nonhematologic reactions <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID611">6</linkHtml>)]</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Temporarily withhold arsenic trioxide and tretinoin.</item>
                                       <item>When the adverse reaction resolves to no more than mild (grade 1), resume arsenic trioxide and tretinoin reduced by 2 dose levels (see <linkHtml href="#ID582">Table 3</linkHtml> below). </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Moderate (grade 2) nonhematologic reactions <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID611">6</linkHtml>)]</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Reduce the dose of arsenic trioxide and/or tretinoin by 1 dose level (see <linkHtml href="#ID582">Table 3</linkHtml> below). </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Leukocytosis (WBC count greater than 10 Gi/L) <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID614">6.1</linkHtml>)]</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Administer hydroxyurea.</item>
                                       <item>Hydroxyurea may be discontinued when the WBC declines below 10 Gi/L.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Myelosuppression, defined by 1 or more of the following:<br/> -   absolute neutrophil count less than 1 Gi/L<br/> -   platelets less than 50 Gi/L lasting more than 5 weeks<br/>
                                    <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID611">6</linkHtml>)]</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Consider reducing the dose of arsenic trioxide and</item>
                                    </list>
 tretinoin by 1 dose level (see <linkHtml href="#ID582">Table 3</linkHtml> below).<br/>
                                    <list listType="unordered" styleCode="disc">
                                       <item>If myelosuppression lasts ≥ 50 days or occurs on 2 consecutive cycles, assess a marrow aspirate for remission status. In the case of molecular remission, resume arsenic trioxide and tretinoin at 1 dose level lower (see <linkHtml href="#ID582">Table 3</linkHtml> below).</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID582" width="81%" styleCode="Noautorules">
                           <caption> Table 3 Dose Reduction Levels for Hematologic and Nonhematologic Toxicities </caption>
                           <col width="34%"/>
                           <col width="32%"/>
                           <col width="32%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">*Rounded to the nearest 10 mg increment</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Dose Level</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Arsenic trioxide</content>
                                    <br/>
                                    <content styleCode="bold"> mg/kg intravenously</content>
                                    <br/>
                                    <content styleCode="bold"> once daily</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Tretinoin* mg/m2 orally twice</content>
                                    <br/>
                                    <content styleCode="bold"> daily</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> Starting level<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.15<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 22.5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> -1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.11<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 18.75<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> -2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.10<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 12.5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="center"> -3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.075<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID583">
                     <id root="9ae9e166-2967-4a47-b5d5-2a38eb019395"/>
                     <title>2.4 Preparation and Administration</title>
                     <text>
                        <paragraph ID="ID584">
                           <content styleCode="italics">Reconstitution</content>
                        </paragraph>
                        <paragraph>Dilute arsenic trioxide with 100 to 250 mL 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP, using proper aseptic technique, immediately after withdrawal from the vial. Do not save any unused portions for later administration.</paragraph>
                        <paragraph>After dilution, store arsenic trioxide for no more than 24 hours at room temperature and 48 hours when refrigerated.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Administration</content>
                        </paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                        <paragraph>Administer arsenic trioxide as an intravenous infusion over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. A central venous catheter is not required.</paragraph>
                        <paragraph>The arsenic trioxide vial is single-dose and does not contain any preservatives. Discard unused portions of each vial properly. Do not mix arsenic trioxide with other medications.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Safe Handling Procedures</content>
                        </paragraph>
                        <paragraph>Arsenic trioxide is a hazardous drug. Follow applicable special handling and disposal procedures.<sup>1</sup> </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID588">
               <id root="37af8eb9-73df-4172-9245-d21b3dd8c97f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID589">Arsenic trioxide injection is an injectable solution for intravenous administration supplied as 10 mg/10 mL of arsenic trioxide in single-dose vials.</paragraph>
               </text>
               <effectiveTime value="20230225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID591">
                           <content styleCode="bold">Injection:</content> 10 mg/10 mL of arsenic trioxide in single-dose vial (<linkHtml href="#ID588">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID592">
               <id root="cf90e2aa-39c7-4037-ae72-16b84c9561d0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID593">Arsenic trioxide is contraindicated in patients with hypersensitivity to arsenic.</paragraph>
               </text>
               <effectiveTime value="20230225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID595">Hypersensitivity to arsenic. (<linkHtml href="#ID592">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID596">
               <id root="f01a8b33-952f-45a4-b673-ea1b86bd620b"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID610" styleCode="Disc">
                           <item>Hepatotoxicity: Elevated aspartate aminotransferase (AST), alkaline phosphatase and serum bilirubin have occurred in patients with newly-diagnosed low-risk APL treated with arsenic trioxide in combination with tretinoin. Monitor hepatic function tests at least twice weekly during induction and at least once weekly during consolidation. Withhold arsenic trioxide for certain elevations in AST, alkaline phosphatase and bilirubin and resume at reduced dose upon resolution. (<linkHtml href="#ID579">2.3</linkHtml>, <linkHtml href="#ID603">5.4</linkHtml>)</item>
                           <item>Carcinogenesis: Arsenic trioxide is a human carcinogen. Monitor patients for the development of second primary malignancies. (<linkHtml href="#ID605">5.5</linkHtml>)</item>
                           <item>Embryo-Fetal Toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception. (<linkHtml href="#ID607">5.6</linkHtml>, <linkHtml href="#ID625">8.1</linkHtml>, <linkHtml href="#ID629">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID597">
                     <id root="fb6e4454-de8a-4924-a044-ae7bc83d1000"/>
                     <title>5.1 Differentiation Syndrome</title>
                     <text>
                        <paragraph ID="ID598">Differentiation syndrome, which may be life-threatening or fatal, has been observed in patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide. In clinical trials, 16% to 23% of patients treated with arsenic trioxide for APL developed differentiation syndrome. Signs and symptoms include unexplained fever, dyspnea, hypoxia, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusion, weight gain, peripheral edema, hypotension, renal insufficiency, hepatopathy and multi-organ dysfunction. Differentiation syndrome has been observed with and without concomitant leukocytosis, and it has occurred as early as day 1 of induction to as late as the second month induction therapy.</paragraph>
                        <paragraph>When arsenic trioxide is used in combination with tretinoin, prophylaxis with prednisone</paragraph>
                        <paragraph>is recommended during the induction cycle <content styleCode="italics">[see Dosage and Administration (2.1)].</content>
                        </paragraph>
                        <paragraph>If differentiation syndrome is suspected, temporarily withhold arsenic trioxide and immediately initiate dexamethasone 10 mg intravenously every 12 hours and hemodynamic monitoring until resolution of signs and symptoms for a minimum of 3 days <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID579">2.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID599">
                     <id root="241c4b74-35ce-404a-b22b-1923a70a8ac0"/>
                     <title>5.2 Cardiac Conduction Abnormalities</title>
                     <text>
                        <paragraph ID="ID600">Patients treated with arsenic trioxide can develop QTc prolongation, torsade de pointes, and complete atrioventricular block. In the clinical trials of patients with newly-diagnosed low-risk APL treated with arsenic trioxide in combination with tretinoin, 11% experienced QTc (Framingham formula) prolongation &gt; 450 msec for men and &gt; 460 msec for women throughout the treatment cycles. In the clinical trial of patients with relapsed or refractory APL treated with arsenic trioxide monotherapy, 40% had at least one ECG tracing with a QTc interval greater than 500 msec. A prolonged QTc was observed between 1 and 5 weeks after start of arsenic trioxide infusion, and it usually resolved by 8 weeks after arsenic trioxide infusion. There are no data on the effect of arsenic trioxide on the QTc interval during the infusion of the drug. </paragraph>
                        <paragraph>The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. The risk may be increased when arsenic trioxide is coadministered with medications that can lead to electrolyte abnormalities (such as diuretics or amphotericin B) <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID622">7</linkHtml>)]</content>.</paragraph>
                        <paragraph>Prior to initiating therapy with arsenic trioxide, assess the QTc interval by electrocardiogram, correct pre-existing electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide to patients with a ventricular arrhythmia or prolonged QTc. If possible, discontinue drugs that are known to prolong the QTc interval. If it is not possible to discontinue the interacting drug, perform cardiac monitoring frequently <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID622">7</linkHtml>)].</content> During arsenic trioxide therapy, maintain potassium concentrations above 4 mEq/L and magnesium concentrations above 1.8 mg/dL. Monitor ECG weekly, and more frequently for clinically unstable patients. </paragraph>
                        <paragraph>For patients who develop a QTc Framingham greater than 450 msec for men or greater than 460 msec for women, withhold arsenic trioxide and any medication known to prolong the QTc interval. Correct electrolyte abnormalities. When the QTc normalizes and electrolyte abnormalities are corrected, resume arsenic trioxide at a reduced dose <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID579">2.3</linkHtml>)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID601">
                     <id root="76fd7a2a-268d-44a5-8a27-1a26e7e106f6"/>
                     <title>5.3 Encephalopathy</title>
                     <text>
                        <paragraph ID="ID602">Serious encephalopathies were reported in patients receiving arsenic trioxide. Monitor patients for neurological symptoms such as confusion, decreased level of consciousness, seizures, cognitive deficits, ataxia, visual symptoms and ocular motor dysfunction. Advise patients and caregivers of the need for close observation. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <content styleCode="underline">Wernicke's Encephalopathy</content>
                              </content>
                           </content>
                        </paragraph>
                        <paragraph>Wernicke's encephalopathy occurred in patients receiving arsenic trioxide. Wernicke's encephalopathy is a neurologic emergency that can be prevented and treated with thiamine. Consider testing thiamine levels in patients at risk for thiamine deficiency (e.g., chronic alcohol use, malabsorption, nutritional deficiency, concomitant use of furosemide). Administer parenteral thiamine in patients with or at risk for thiamine deficiency. Monitor patients for neurological symptoms and nutritional status while receiving arsenic trioxide. If Wernicke's encephalopathy is suspected, immediately interrupt arsenic trioxide and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize.</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
               <component>
                  <section ID="ID603">
                     <id root="9a8a274d-6d7b-44b3-a96c-1986b577d13a"/>
                     <title>5.4 Hepatotoxicity</title>
                     <text>
                        <paragraph ID="ID604">In the clinical trials, 44% of patients with newly-diagnosed low-risk APL treated with arsenic trioxide in combination with tretinoin experienced elevated aspartate aminotransferase (AST), alkaline phosphatase and/or serum bilirubin. These abnormalities resolved with temporary discontinuation of arsenic trioxide and/or tretinoin.</paragraph>
                        <paragraph>Long-term liver abnormalities can occur in patients with APL treated with arsenic trioxide in combination with tretinoin. In a published series, mild liver dysfunction and hepatic steatosis were seen in 15% and 43%, respectively, of patients at a median of 7 years (range 0 to 14 years) after treatment with arsenic trioxide in combination with tretinoin.</paragraph>
                        <paragraph>During treatment with arsenic trioxide, monitor hepatic function tests at least twice weekly during induction and at least once weekly during consolidation. Withhold arsenic trioxide and/or tretinoin if elevations in AST or alkaline phosphatase occur to greater than 5 times the upper limit of normal and/or elevation in serum total bilirubin occurs to greater than 3 times the upper limit of normal and resume at reduced dose upon resolution <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID579">2.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID605">
                     <id root="3239e8a7-ff76-4654-9ac8-e27f1da83602"/>
                     <title>5.5 Carcinogenesis</title>
                     <text>
                        <paragraph ID="ID606">The active ingredient of arsenic trioxide, is a human carcinogen. Monitor patients for the development of second primary malignancies.</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
               <component>
                  <section ID="ID607">
                     <id root="d4ae8479-1833-4a83-aa70-3a31bc288529"/>
                     <title>5.6 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph ID="ID608">Arsenic trioxide can cause fetal harm when administered to a pregnant woman. Arsenic trioxide was embryolethal and teratogenic in rats when administered on gestation day 9 at a dose approximately 10 times the recommended human daily dose on a mg/m<sup>2</sup> basis. A related trivalent arsenic, sodium arsenite, produced teratogenicity when administered during gestation in mice at a dose approximately 5 times the projected human dose on a mg/m<sup>2</sup> basis and in hamsters at an intravenous dose approximately equivalent to the projected human daily dose on a mg/m<sup>2</sup> basis. </paragraph>
                        <paragraph>Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with arsenic trioxide and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with arsenic trioxide and for 3 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID625">8.1</linkHtml>, <linkHtml href="#ID629">8.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID611">
               <id root="adde3922-aa2f-4393-9464-b9d0295dcc99"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID612">The following clinically significant adverse reactions are described elsewhere in the labeling.:</paragraph>
                  <list listType="unordered" ID="ID613" styleCode="Disc">
                     <item>Differentiation Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID597">5.1</linkHtml>)]</content>
                     </item>
                     <item>Cardiac Conduction Abnormalities <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID599">5.2</linkHtml>)]</content>
                     </item>
                     <item>Encephalopathy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID601">5.3</linkHtml>)]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID603">5.4</linkHtml>)]</content>
                     </item>
                     <item>Carcinogenesis<content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID605">5.5</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID621">The most common adverse reactions (&gt; 30%) are nausea, cough, fatigue, pyrexia, headache, abdominal pain, vomiting, tachycardia, diarrhea, dyspnea, hypokalemia, leukocytosis, hyperglycemia, hypomagnesemia, insomnia, dermatitis, edema, QTc prolongation, rigors, sore throat, arthralgia, paresthesia, and pruritus (<linkHtml href="#ID614">6.1</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID614">
                     <id root="53714bf9-a3e5-4ad4-8462-5070774bdc26"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="ID615">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Newly-Diagnosed Low-Risk APL</content>
                           </content>
                        </paragraph>
                        <paragraph>The safety of arsenic trioxide in combination with tretinoin was evaluated in Study APL0406, a randomized trial comparing arsenic trioxide plus tretinoin (n=129) versus chemotherapy plus tretinoin (n=137) in patients with newly-diagnosed APL <content styleCode="italics">[see Clinical</content> <content styleCode="italics">Studies (14.1)]</content>. In the arsenic trioxide /tretinoin group, 98% of patients completed induction therapy and 89% completed at least three consolidation cycles. In the chemotherapy/tretinoin group, 96% completed induction therapy and 87% patients completed all three courses of consolidation therapy.</paragraph>
                        <paragraph>Serious adverse reactions were reported in 25% of patients on the arsenic trioxide /tretinoin arm and 24% on the chemotherapy/tretinoin arm. The serious adverse reactions reported in ≥ 2% of patients who received arsenic trioxide /tretinoin were abnormal liver tests, differentiation syndrome, dyspnea, pneumonia, and other infections. Fatal adverse reactions were reported in 1 (1%) patient on the arsenic trioxide /tretinoin arm and 8 (6%) patients on the chemotherapy/tretinoin arm.</paragraph>
                        <paragraph>Arsenic trioxide /tretinoin was discontinued due to toxicity in 1 patient during induction and in 4 patients during the first three consolidation courses, whereas chemotherapy/tretinoin was discontinued due to toxicity in 4 patients during induction and in 6 patients during consolidation.</paragraph>
                        <paragraph>Selected hematologic and nonhematologic toxicities that occurred during induction or</paragraph>
                        <paragraph>consolidation are presented in Table 4.</paragraph>
                        <table ID="ID687" width="100%" styleCode="Noautorules">
                           <caption> Table 4Select Adverse Reactions of Arsenic trioxide in Combination with Tretinoin in Patients with Newly-Diagnosed APL in Study APL0406 </caption>
                           <col width="39%"/>
                           <col width="12%"/>
                           <col width="15%"/>
                           <col width="15%"/>
                           <col width="16%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">*Mostly cases of reversible peripheral neuropathy</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <br/>
                                    <content styleCode="bold"> Adverse Reaction</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <br/>
                                    <content styleCode="bold"> Induction</content>
                                    <br/> n (%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> First Consolidation</content>
                                    <br/> n (%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Second Consolidation</content>
                                    <br/> n (%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Third Consolidation</content>
                                    <br/> n (%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Thrombocytopenia &gt; 15 days (Grade 3-4) arsenic trioxide /tretinoin<br/> Chemotherapy/tretinoin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 74 (58%)<br/> 120 (88%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 6 (5%)<br/> 17 (14%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 6 (5%)<br/> 77 (63%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 8 (7%)<br/> 26 (22%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Neutropenia &gt;15 days (Grade 3-4)<br/> arsenic trioxide /tretinoin Chemotherapy/tretinoin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 61 (48%)<br/> 109 (80%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 8 (7%)<br/> 40 (32%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 7 (6%)<br/> 90 (73%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 5 (4%)<br/> 28 (24%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hepatic toxicity (Grade 3-4) arsenic trioxide /tretinoin<br/> Chemotherapy/tretinoin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 51 (40%)<br/> 4 (3%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 5 (4%)<br/> 1 (1%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 1 (1%)<br/> 0 (0%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 0 (0%)<br/> 0 (0%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Infection and fever of unknown origin<br/> arsenic trioxide /tretinoin Chemotherapy/tretinoin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 30 (23%)<br/> 75 (55%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 10 (8%)<br/> 8 (6%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 4 (3%)<br/> 46 (38%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 2 (2%)<br/> 2 (2%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hypertriglyceridemia arsenic trioxide /tretinoin Chemotherapy/tretinoin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 29 (22%)<br/> 29 (22%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 22 (18%)<br/> 19 (15%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 17 (14%)<br/> 10 (8%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 16 (14%)<br/> 13 (11%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Hypercholesterolemia<br/> arsenic trioxide /tretinoin Chemotherapy/tretinoin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 14 (10%)<br/> 12 (9%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 19 (16%)<br/> 12 (10%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 19 (16%)<br/> 12 (10%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 16 (14%)<br/> 11 (9%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> QT prolongation arsenic trioxide /tretinoin Chemotherapy/tretinoin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 11 (9%)<br/> 1 (1%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 3 (2%)<br/> 0 (0%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 3 (2%)<br/> 0 (0%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <br/> 2 (2%)<br/> 0 (0%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Gastrointestinal toxicity (Grade 3-4)<br/> arsenic trioxide /tretinoin Chemotherapy/tretinoin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 (2%)<br/> 25 (18%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 (0%)<br/> 1 (1%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 (0%)<br/> 6 (5%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 (0%)<br/> 0 (0%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Neurotoxicity* arsenic trioxide /tretinoin Chemotherapy/tretinoin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 (1%)<br/> 0 (0%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 5 (4%)<br/> 0 (0%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6 (5%)<br/> 0 (0%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7 (6%)<br/> 0 (0%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Cardiac function (Grade 3-4)<br/> arsenic trioxide /tretinoin Chemotherapy/tretinoin<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 (0%)<br/> 5 (4%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 (0%)<br/> 0 (0%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 (0%)<br/> 0 (0%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 (0%)<br/> 0 (0%)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID686">
                           <content styleCode="bold">
                              <content styleCode="italics">Relapsed or Refractory APL</content>
                           </content>
                        </paragraph>
                        <paragraph>Safety information was available for 52 patients with relapsed or refractory APL who participated in clinical trials of arsenic trioxide. Forty patients in the Study PLRXAS01 received the recommended dose of 0.15 mg/kg, of whom 28 completed both induction and consolidation cycles. An additional 12 patients with relapsed or refractory APL received doses generally similar to the recommended dose. </paragraph>
                        <paragraph>Serious adverse reactions observed in the 40 patients with refractory or relapsed APL enrolled in Study PLRXAS01 included differentiation syndrome (n=3), hyperleukocytosis (n=3), QTc interval ≥ 500 msec (n=16, 1 with torsade de pointes), atrial dysrhythmias (n=2), and hyperglycemia (n=2).</paragraph>
                        <paragraph>The most common adverse reactions (&gt; 30%) were nausea, cough, fatigue, pyrexia, headache, abdominal pain, vomiting, tachycardia, diarrhea, dyspnea, hypokalemia, leukocytosis, hyperglycemia, hypomagnesemia, insomnia, dermatitis, edema, QTc prolongation, rigors, sore throat, arthralgia, paresthesia, and pruritus.</paragraph>
                        <paragraph>Table 5 describes the adverse reactions in patients aged 5 to 73 years with APL who received arsenic trioxide at the recommended dose. Similar adverse reactions profiles were seen in the other patient populations who received arsenic trioxide.</paragraph>
                        <table ID="ID616" width="100%" styleCode="Noautorules">
                           <caption>  Table 5 Adverse Reactions (≥ 5%) in Patients with Relapsed or Refractory APL Who Received Arsenic Trioxide in Study PLRXAS01 </caption>
                           <col width="50%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Body System</content>
                                    <br/> Adverse reaction<br/>
                                 </td>
                                 <td colspan="2" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Any Grade</content>
                                    <br/>
                                    <content styleCode="bold"> Adverse Reactions</content>
                                    <br/>
                                 </td>
                                 <td colspan="2" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Grade ≥3</content>
                                    <br/>
                                    <content styleCode="bold"> Adverse Reactions</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> n</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> %</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> n</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> %</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Gastrointestinal disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Nausea<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 30<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 75<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Abdominal pain (lower &amp; upper)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 23<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 58<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Vomiting<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 23<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 58<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Diarrhea<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 21<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 53<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Sore throat<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 14<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 35<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Constipation<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 11<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 28<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Anorexia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 9<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 23<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Appetite decreased<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 15<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Loose stools<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dyspepsia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Oral blistering<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Fecal incontinence<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Gastrointestinal hemorrhage<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dry mouth<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Abdominal tenderness<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Diarrhea hemorrhagic<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Abdominal distension<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Respiratory</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Cough<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 26<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 65<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dyspnea<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 21<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 53<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Epistaxis<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 25<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hypoxia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 9<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 23<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Pleural effusion<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 20<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Post nasal drip<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Wheezing<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Decreased breath sounds<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Crepitations<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Rales<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hemoptysis<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Tachypnea<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Rhonchi<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> General disorders and administration site conditions</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Fatigue<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 25<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 63<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Pyrexia (fever)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 25<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 63<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Edema - non-specific<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 16<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 40<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Rigors<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 15<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 38<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Chest pain<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 25<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Injection site pain<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 20<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Pain - non-specific<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 15<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Injection site erythema<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Weight gain<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Injection site edema<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Weakness<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hemorrhage<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Weight loss<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Drug hypersensitivity<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Nervous system disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Headache<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 24<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 60<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Insomnia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 17<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 43<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Paresthesia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 33<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dizziness (excluding vertigo)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 9<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 23<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Tremor<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Convulsion<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Somnolence<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Coma<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Cardiac disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Tachycardia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 22<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 55<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> ECG QT corrected interval prolonged<br/> &gt; 500 msec<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 16<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 40<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Palpitations<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> ECG abnormal other than QT interval prolongation<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Metabolism and nutrition disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hypokalemia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 20<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 50<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hypomagnesemia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 45<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hyperglycemia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 45<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> ALT increased<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 20<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hyperkalemia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> AST increased<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hypocalcemia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hypoglycemia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Acidosis<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Hematologic disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Leukocytosis<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 20<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 50<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Anemia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 20<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Thrombocytopenia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Febrile neutropenia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Neutropenia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Disseminated intravascular coagulation<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Lymphadenopathy<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Skin and subcutaneous tissue disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dermatitis<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 17<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 43<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Pruritus<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 33<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Ecchymosis<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 20<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dry skin<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 15<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Erythema - non-specific<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Increased sweating<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Facial edema<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Night sweats<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Petechiae<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hyperpigmentation<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Non-specific skin lesions<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Urticaria<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Local exfoliation<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Eyelid edema<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Musculoskeletal, connective tissue, and bone disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Arthralgia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 33<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Myalgia<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 25<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Bone pain<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 9<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 23<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Back pain<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 18<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Neck pain<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Pain in limb<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Psychiatric disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Anxiety<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 12<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 30<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Depression<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 20<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Agitation<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Confusion<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Vascular disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hypotension<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 25<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Flushing<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Hypertension<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Pallor<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Infections and infestations</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Sinusitis<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 20<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Herpes simplex<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Upper respiratory tract infection<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Bacterial infection - non-specific<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Herpes zoster<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Nasopharyngitis<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Oral candidiasis<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Sepsis<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Reproductive system disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Vaginal hemorrhage<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 13<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Intermenstrual bleeding<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Ocular disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Eye irritation<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Blurred vision<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Dry eye<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Painful red eye<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Renal and urinary disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Renal failure<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Renal impairment<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Oliguria<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Incontinence<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Ear disorders</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Earache<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> Tinnitus<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID617">
                           <content styleCode="bold">
                              <content styleCode="italics">Other Clinically Relevant Adverse Reactions</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Leukocytosis</content>
                        </paragraph>
                        <paragraph>Arsenic trioxide can induce proliferation of leukemic promyelocytes resulting in a rapid increase in white blood cell count. Leukocytosis greater than 10 Gi/L developed during induction therapy in 43% patients receiving arsenic trioxide /tretinoin for newly-diagnosed low-risk APL and in 50% of patients receiving arsenic trioxide monotherapy for relapsed/refractory APL. In the relapsed/refractory setting, a relationship did not exist between baseline WBC counts and development of hyperleukocytosis nor baseline WBC counts and peak WBC counts. </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID618">
                     <id root="dfb0ae48-9c12-4f50-be45-2a7bac06b704"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID619">The following adverse reactions have been identified during postapproval use of arsenic trioxide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Cardiac disorders: </content>Ventricular extrasystoles in association with QT prolongation, ventricular tachycardia in association with QT prolongation, including torsade de pointes, atrioventricular block, and congestive heart failure</paragraph>
                        <paragraph>
                           <content styleCode="bold">Ear and labyrinth disorders:</content> Deafness</paragraph>
                        <paragraph>
                           <content styleCode="bold">Hematologic disorders:</content> Pancytopenia, bone marrow necrosis</paragraph>
                        <paragraph>
                           <content styleCode="bold">Infections: </content>Herpes zoster</paragraph>
                        <paragraph>
                           <content styleCode="bold">Investigations: </content>Gamma-glutamyltransferase increased</paragraph>
                        <paragraph>
                           <content styleCode="bold">Musculoskeletal and connective tissue disorders: </content>Bone pain, myalgia, rhabdomyolysis</paragraph>
                        <paragraph>
                           <content styleCode="bold">Neoplasms benign, malignant and unspecified: </content>Melanoma, pancreatic cancer, squamous cell carcinoma</paragraph>
                        <paragraph>
                           <content styleCode="bold">Nervous system disorders:</content> Peripheral neuropathy, paresis, seizures, confusion, encephalopathy, Wernicke's encephalopathy, posterior reversible encephalopathy syndrome</paragraph>
                        <paragraph>
                           <content styleCode="bold">Skin and subcutaneous tissue disorders: </content>Toxic epidermal necrolysis</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID622">
               <id root="a7427eb5-7a76-4720-9605-0fe0be8ae322"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph ID="ID623">
                     <content styleCode="bold">Drugs That Can Prolong the QT/QTc Interval</content>
                  </paragraph>
                  <paragraph>Concomitant use of these drugs and arsenic trioxide may increase the risk of serious QT/QTc interval prolongation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID597">5.1</linkHtml>)].</content> Discontinue or replace with an alternative drug that does not prolong the QT/QTc interval while the patient is using arsenic trioxide. Monitor ECGs more frequently in patients when it is not feasible to avoid concomitant use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Drugs That Can Lead to Electrolyte Abnormalities</content>
                  </paragraph>
                  <paragraph>Electrolyte abnormalities increase the risk of serious QT/QTc interval prolongation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID597">5.1</linkHtml>)].</content> Avoid concomitant use of drugs that can lead to electrolyte abnormalities. Monitor electrolytes more frequently in patients who must receive concomitant use of these drugs and arsenic trioxide.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Drugs That Can Lead to Hepatotoxicity</content>
                  </paragraph>
                  <paragraph>Concomitant use of these drugs and arsenic trioxide particularly when given in combination with tretinoin, may increase the risk of serious hepatotoxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID603">5.4</linkHtml>)].</content> Discontinue or replace with an alternative drug that does not cause hepatotoxicity while the patient is using arsenic trioxide. Monitor liver function tests more frequently in patients when it is not feasible to avoid concomitant use.  </paragraph>
               </text>
               <effectiveTime value="20250512"/>
            </section>
         </component>
         <component>
            <section ID="ID624">
               <id root="45c6e39d-1350-4483-83b7-03b3c4cb1738"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250512"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID640" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Lactation:</content> Advise not to breastfeed. (<linkHtml href="#ID627">8.2</linkHtml>)</item>
                           <item>
                              <content styleCode="bold">Renal Impairment:</content> Monitor patients with severe renal impairment (creatinine clearance less than 30 mL/min) for toxicity when treated with arsenic trioxide; dose reduction may be warranted. (<linkHtml href="#ID635">8.6</linkHtml>)</item>
                           <item>
                              <content styleCode="bold">Hepatic Impairment:</content> Monitor patients with severe hepatic impairment (Child-Pugh Class C) for toxicity when treated with arsenic trioxide. (<linkHtml href="#ID637">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID625">
                     <id root="211e426c-a4b4-4966-b7fd-794393d5d9a0"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID626">
                           <content styleCode="italics">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on the mechanism of action <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID648">12.1</linkHtml>)]</content> and findings in animal studies, arsenic trioxide can cause fetal harm when administered to a pregnant woman. Arsenic trioxide was embryolethal and teratogenic in rats when administered on gestation day 9 at a dose approximately 10 times the recommended human daily dose on a mg/m<sup>2</sup> basis <content styleCode="italics">(see Data)</content>. A related trivalent arsenic, sodium arsenite, produced teratogenicity when administered during gestation in mice at a dose approximately 5 times the projected human dose on a mg/m<sup>2</sup> basis and in hamsters at an intravenous dose approximately equivalent to the projected human daily dose on a mg/m<sup>2</sup> basis. There are no studies with the use of arsenic trioxide in pregnant women, and limited published data on arsenic trioxide use during pregnancy are insufficient to inform a drug-associated risk of major birth defects and miscarriage. Advise pregnant women of the potential risk to a fetus.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Human Data</content>
                        </paragraph>
                        <paragraph>One patient was reported to deliver a live infant with no reported congenital anomalies after receiving arsenic trioxide during the first five months of pregnancy. A second patient became pregnant three months after discontinuing arsenic trioxide and was reported to have a normal pregnancy outcome. A third patient was a pregnant healthcare provider who experienced dermal contact with liquid arsenic trioxide and had a normal pregnancy outcome after treatment and monitoring. A fourth patient who became pregnant while receiving arsenic trioxide had a miscarriage. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Animal Data</content>
                        </paragraph>
                        <paragraph>Studies in pregnant mice, rats, hamsters, and primates have shown that inorganic arsenicals cross the placental barrier when given orally or by injection. An increase in resorptions, neural-tube defects, anophthalmia and microphthalmia were observed in rats administered 10 mg/kg of arsenic trioxide on gestation day 9 (approximately 10 times the recommended human daily dose on a mg/m<sup>2</sup> basis). Similar findings occurred in mice administered a 10 mg/kg dose of a related trivalent arsenic, sodium arsenite (approximately 5 times the projected human dose on a mg/m<sup>2</sup> basis), on gestation days 6, 7, 8, or 9. Intravenous injection of 2 mg/kg sodium arsenite (approximately equivalent to the projected human daily dose on a mg/m<sup>2</sup> basis) on gestation day 7 (the lowest dose tested) resulted in neural-tube defects in hamsters.</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
               <component>
                  <section ID="ID627">
                     <id root="4301c6d1-cffe-4bd3-bb6a-efbadd5383b4"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID628">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Arsenic trioxide is excreted in human milk. There are no data on the effects of arsenic trioxide on the breastfed child or on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with arsenic trioxide and for 2 weeks after the final dose.</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
               <component>
                  <section ID="ID629">
                     <id root="97dd0528-40a3-463a-8042-f5989ecf77c0"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph ID="ID630">Arsenic trioxide can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID625">8.1</linkHtml>)]. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Pregnancy Testing </content>
                        </paragraph>
                        <paragraph>Conduct pregnancy testing in females of reproductive potential prior to initiation of arsenic trioxide.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Contraception</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment with arsenic trioxide and for 6 months after the final dose.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with arsenic trioxide and for 3 months after the final dose.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Infertility</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Based on testicular toxicities including decreased testicular weight and impaired spermatogenesis observed in animal studies, arsenic trioxide may impair fertility in males of reproductive potential <content styleCode="italics">[see Nonclinical Toxicology (<linkHtml href="#ID655">13.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
               <component>
                  <section ID="ID631">
                     <id root="60ab91e3-55ac-47ab-91a6-156f89816c3d"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID632">The safety and efficacy of arsenic trioxide in combination with tretinoin in pediatric patients has not been established.</paragraph>
                        <paragraph>The safety and efficacy of arsenic trioxide as a single agent for treatment of pediatric patients with relapsed or refractory APL is supported by the pivotal phase 2 study in 40 patients with relapsed or refractory APL. Five patients below the age of 18 years (age range: 5 years to 16 years) were treated with arsenic trioxide at the recommended dose of 0.15 mg/kg/day. A literature review included an additional 17 patients treated with arsenic trioxide for relapsed or refractory APL, with ages ranging from 4 years to 21 years. No differences in efficacy and safety were observed by age. </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID633">
                     <id root="2d9b5cd8-1cf0-4cb4-b5d1-079976b69d30"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID634">Use of arsenic trioxide in combination with tretinoin in newly-diagnosed adult patients with low-risk APL is supported by a randomized, controlled trial that included 16 patients between the ages of 60 years and 70 years. No overall differences in safety or effectiveness were observed between these patients and younger patients. A literature review included an additional 77 patients aged 60 years to 84 years who were treated with arsenic trioxide in combination with tretinoin as part of induction and consolidation therapy for low-and high-risk APL. These studies showed lower survival rates in older patients. Monitor elderly patients frequently during treatment with arsenic trioxide.</paragraph>
                        <paragraph>Use of arsenic trioxide as monotherapy in patients with relapsed or refractory APL is supported by the open-label, single-arm trial that included 6 patients aged 65 and older (range: 65 to 73 years). A literature review included an additional 4 patients aged 69 to 72 years who were treated with arsenic trioxide for relapsed or refractory APL. No overall differences in safety or effectiveness were observed between these patients and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID635">
                     <id root="0c86dcb8-b10d-428f-919f-abeeb4e3cb7c"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID636">Exposure of arsenic trioxide may be higher in patients with severe renal impairment <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID652">12.3</linkHtml>)]</content>. Monitor patients with severe renal impairment (creatinine clearance [CLcr] less than 30 mL/min) frequently for toxicity; a dose reduction may be warranted.</paragraph>
                        <paragraph>The use of arsenic trioxide in patients on dialysis has not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
               <component>
                  <section ID="ID637">
                     <id root="3a255ebb-284a-477c-a619-f3b528fd78d6"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID638">Since limited data are available across all hepatic impairment groups, caution is advised in the use of arsenic trioxide in patients with hepatic impairment <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID652">12.3</linkHtml>)]</content>. Monitor patients with severe hepatic impairment (Child-Pugh Class C) frequently for toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID641">
               <id root="d7ab83a9-79cd-44bf-9570-d4c57f03a8cd"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID642">
                     <content styleCode="bold">Manifestations</content>
                  </paragraph>
                  <paragraph>Manifestations of arsenic trioxide (arsenic trioxide) overdosage include convulsions, muscle weakness, and confusion. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Management</content>
                  </paragraph>
                  <paragraph>For symptoms of arsenic trioxide overdosage, immediately discontinue arsenic trioxide and consider chelation therapy.</paragraph>
                  <paragraph>A conventional protocol for acute arsenic intoxication includes dimercaprol administered at a dose of 3 mg/kg intramuscularly every 4 hours until immediate life-threatening toxicity has subsided. Thereafter, penicillamine at a dose of 250 mg orally, up to a maximum frequency of four times per day (≤ 1 g per day), may be given.</paragraph>
               </text>
               <effectiveTime value="20230225"/>
            </section>
         </component>
         <component>
            <section ID="ID643">
               <id root="8ae4566a-3872-4a6f-b935-d432f64e36a3"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID644">Arsenic trioxide injection is a sterile injectable solution of arsenic trioxide. The molecular formula of arsenic trioxide in the solid state is As<sub>2</sub>O<sub>3</sub>, with a molecular weight of 197.8 and the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID646">Arsenic trioxide injection is available in 10 mL, single-dose vials containing 10 mg of arsenic trioxide. Arsenic trioxide injection is formulated as a sterile, nonpyrogenic, clear solution of arsenic trioxide in water for injection using sodium hydroxide and dilute hydrochloric acid to adjust to pH 8. Arsenic trioxide injection is preservative-free. Arsenic trioxide, the active ingredient, is present at a concentration of 1 mg/ mL. Inactive ingredients and their respective approximate concentrations are sodium hydroxide (1.2 mg/mL) for solubilization, and hydrochloric acid for pH adjustment to pH 7.5 to 8.5.</paragraph>
               </text>
               <effectiveTime value="20250512"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="db2757aa-d8c7-4114-b4bb-5eeec0df762f-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID647">
               <id root="c6b80cf5-4d03-40e6-8bdf-7c1ab1270d29"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20230225"/>
               <component>
                  <section ID="ID648">
                     <id root="cda3a32d-c0f5-4004-ac72-a9738d7e370f"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID649">The mechanism of action of arsenic trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha.</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
               <component>
                  <section ID="ID650">
                     <id root="94f021b6-1efc-42be-a48c-b850e2a08fc6"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID651">
                           <content styleCode="bold">
                              <content styleCode="italics">Cardiac Electrophysiology</content>
                           </content>
                        </paragraph>
                        <paragraph>In a single-arm trial of arsenic trioxide (0.15 mg/kg daily), 16 of 40 patients (40%) had a QTc interval greater than 500 msec. Prolongation of the QTc was observed between 1 and 5 weeks after arsenic trioxide infusion, and then returned towards baseline by the end of 8 weeks after arsenic trioxide infusion.</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
               <component>
                  <section ID="ID652">
                     <id root="d6a9f24c-3b2c-43f8-9c26-5292de9174c1"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID653">The inorganic, lyophilized form of arsenic trioxide, when placed into solution, immediately forms the hydrolysis product arsenious acid (As<sup>III</sup>). As<sup>III</sup> is the pharmacologically active species of arsenic trioxide. Monomethylarsonic acid (MMA<sup>V</sup>), and dimethylarsinic acid (DMA<sup>V</sup>) are the main pentavalent metabolites formed during metabolism, in addition to arsenic acid (As<sup>V</sup>) a product of As<sup>III</sup> oxidation.</paragraph>
                        <paragraph>The pharmacokinetics of arsenical species ([As<sup>III</sup>], [As<sup>V</sup>], [MMA<sup>V</sup>], [DMA<sup>V</sup>]) were determined in 6 APL patients following once-daily doses of 0.15 mg/kg for 5 days per week. Over the total single-dose range of 7 mg to 32 mg (administered as 0.15 mg/kg), systemic exposure (AUC) appears to be linear.</paragraph>
                        <paragraph>Peak plasma concentrations of arsenious acid (As<sup>III</sup>), the primary active arsenical species were reached at the end of infusion (2 hours). Plasma concentration of As<sup>III</sup> declined in a biphasic manner with a mean elimination half-life of 10 hours to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase. The daily exposure to As<sup>III</sup> (mean AUC<sub>0-24h</sub>) was 194 ng·hr/mL (n=5) on Day 1 of Cycle 1 and 332 ng·hr/mL (n=6) on Day 25 of Cycle 1, which represents an approximate 2-fold accumulation.</paragraph>
                        <paragraph>The primary pentavalent metabolites, MMA<sup>V</sup> and DMA<sup>V</sup>, are slow to appear in plasma (approximately 10 hours to 24 hours after first administration of arsenic trioxide), but, due to their longer half-life, accumulate more upon multiple dosing than does As<sup>III</sup>. The mean estimated terminal elimination half-lives of the metabolites MMA<sup>V</sup> and DMA<sup>V</sup> are 32 hours and 72 hours, respectively. Approximate accumulation ranged from 1.4- to 8-fold following multiple dosing as compared to single-dose administration. As<sup>V</sup> is present in plasma only at relatively low levels.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Distribution</content>
                           </content>
                        </paragraph>
                        <paragraph>The volume of distribution (V<sub>ss</sub>) for As<sup>III</sup> is large (mean 562 L, N=10) indicating that As<sup>III</sup> is widely distributed throughout body tissues. V<sub>ss</sub> is also dependent on body weight and increases as body weight increases.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Elimination</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Much of the As<sup>III</sup> is distributed to the tissues where it is methylated to the less cytotoxic metabolites, monomethylarsonic acid (MMA<sup>V</sup>) and dimethylarsinic acid (DMA<sup>V</sup>) by methyltransferases primarily in the liver. The metabolism of arsenic trioxide also involves oxidation of As<sup>III</sup> to As<sup>V</sup>, which may occur in numerous tissues via enzymatic or nonenzymatic processes. As<sup>V</sup> is present in plasma only at relatively low levels following administration of arsenic trioxide.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Approximately 15% of the administered arsenic trioxide dose is excreted in the urine as unchanged As<sup>III</sup>. The methylated metabolites of As<sup>III</sup> (MMA<sup>V</sup>, DMA<sup>V</sup>) are primarily excreted in the urine. The total clearance of As<sup>III</sup> is 49 L/h and the renal clearance is 9 L/h. Clearance is not dependent on body weight or dose administered over the range of 7 mg to 32 mg.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Specific Populations</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>The effect of renal impairment on the pharmacokinetics of As<sup>III</sup>, As<sup>V</sup>, and the pentavalent metabolites MMA<sup>V</sup> and DMA<sup>V</sup> was evaluated in 20 patients with advanced malignancies. Patients were classified as having normal renal function (creatinine clearance [CLcr] &gt; 80 mL/min, n=6), mild renal impairment (CLcr 50 mL/min to 80 mL/min, n=5), moderate renal impairment (CLcr 30 mL/min to 49 mL/min, n=6), or severe renal impairment (CLcr &lt; 30 mL/min, n=3). Following twice-weekly administration of 0.15 mg/kg over a 2-hour infusion, the mean AUC<sub>0-INF</sub> for As<sup>III</sup> was comparable among the normal, mild and moderate renal impairment groups. However, in the <content styleCode="bold">severe</content> renal impairment group, the mean AUC<sub>0-INF</sub> for As<sup>III</sup> was approximately 48% higher than that in the normal group.</paragraph>
                        <paragraph>Systemic exposure to MMA<sup>V</sup> and DMA<sup>V</sup> tended to be larger in patients with renal impairment; however, the clinical consequences of this increased exposure are not known. As<sup>V</sup> plasma levels were generally below the limit of assay quantitation in patients with impaired renal function <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID635">8.6</linkHtml>)]</content>. The use of arsenic trioxide in patients on dialysis has not been studied.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>The effect of pharmacokinetics of As<sup>III</sup>, As<sup>V</sup>, and the pentavalent metabolites MMA<sup>V</sup> and DMA<sup>V</sup> was evaluated following administration of 0.25 mg/kg to 0.50 mg/kg of arsenic trioxide in patients with hepatocellular carcinoma. Patients were classified as having normal hepatic function (n=4), mild hepatic impairment (Child-Pugh class A, n=12), moderate hepatic impairment (Child-Pugh class B, n=3), or severe hepatic impairment (Child-Pugh class C, n=1). No clear trend toward an increase in systemic exposure to As<sup>III</sup>, As<sup>V</sup>, MMA<sup>V</sup> or DMA<sup>V</sup> was observed with decreasing level of hepatic function as assessed by dose-normalized (per mg dose) AUC in the mild and moderate hepatic impairment groups. However, the one patient with severe hepatic impairment had mean dose-normalized AUC<sub>0‑24h</sub> and C<sub>max</sub> values 40% and 70% higher, respectively, than those patients with normal hepatic function. The mean dose-normalized trough plasma levels for both MMA<sup>V</sup> and DMA<sup>V</sup> in this severely hepatically impaired patient were 2.2-fold and 4.7-fold higher, respectively, than those in the patients with normal hepatic function <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID637">8.7</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>Following intravenous administration of 0.15 mg/kg/day of arsenic trioxide in 10 APL patients (median age = 13.5 years, range 4-20 years), the daily exposure to As<sup>III</sup> (mean AUC<sub>0-24h</sub>) was 317 ng·hr/mL on Day 1 of Cycle 1 <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID631">8.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Drug Interaction Studies</content>
                           </content>
                        </paragraph>
                        <paragraph>No formal assessments of pharmacokinetic drug-drug interactions between arsenic trioxide and other drugs have been conducted. The methyltransferases responsible for metabolizing arsenic trioxide are not members of the cytochrome P450 family of isoenzymes. In vitro incubation of arsenic trioxide with human liver microsomes showed no inhibitory activity on substrates of the major cytochrome P450 (CYP) enzymes such as 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, and 4A9/11. The pharmacokinetics of drugs that are substrates for these CYP enzymes are not expected to be affected by concomitant treatment with arsenic trioxide. </paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID654">
               <id root="9c2f5a49-7b1f-4bd7-aab1-9e4f80d56d77"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230225"/>
               <component>
                  <section ID="ID655">
                     <id root="cfa1856e-330b-40b8-9f2f-c7fa55908e87"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID656">Carcinogenicity studies have not been conducted with arsenic trioxide <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID607">5.6</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Arsenic trioxide and trivalent arsenite salts have not been demonstrated to be mutagenic to bacteria, yeast, or mammalian cells. Arsenite salts are clastogenic in vitro (human fibroblast, human lymphocytes, Chinese hamster ovary cells, Chinese hamster V79 lung cells). Trivalent arsenic was genotoxic in the chromosome aberrations assay and micronucleus bone marrow assay in mice.</paragraph>
                        <paragraph>The effect of arsenic on fertility has not been adequately studied in humans. Decreased testicular weight and impaired spermatogenesis have been reported in animal studies. Male Wistar rat pups were administered 1.5 mg/kg sodium arsenite solution via the intraperitoneal route from postnatal days 1 to 14 and testes were collected for evaluation on postnatal days 15, 21, and 50. Results of this study revealed an altered morphology of the seminiferous tubules along with degeneration of spermatogenic cells, increased number of sperm with abnormal morphology, and decreased sperm counts. In beagle dogs administered intravenous arsenic trioxide for 90 days, reduced inner cell layers within seminiferous tubules and significantly decreased numbers of spermatocytes, spermatozoa, and sperm cells were observed at doses of 1 mg/kg/day and higher. The 1 mg/kg/day dose is approximately 3 times the recommended human daily dose on a mg/m<sup>2</sup> basis.</paragraph>
                     </text>
                     <effectiveTime value="20230225"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID657">
               <id root="47cd4aca-be0c-41ea-8cf3-7f7de7e2de68"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250512"/>
               <component>
                  <section ID="ID688">
                     <id root="03478cdb-e45d-4a14-8ab0-4dc13475a60f"/>
                     <title>14.1 Newly-Diagnosed Low-Risk APL</title>
                     <text>
                        <paragraph ID="ID689">Arsenic trioxide in combination with tretinoin was investigated in Study APL0406 (NCT00482833), a multicenter, randomized, open-label trial in patients with newly diagnosed low-risk APL (white blood cell count at diagnosis ≤10 Gi/L). The patients were randomized 1:1 to receive arsenic trioxide /tretinoin for induction and consolidation or chemotherapy/tretinoin for induction, consolidation, and maintenance.</paragraph>
                        <paragraph>Patients in the arsenic trioxide /tretinoin group received induction treatment with arsenic trioxide 0.15 mg/kg intravenously once daily in combination with tretinoin 22.5 mg/m2 (rounded to the nearest 10 mg increment) orally twice daily until hematologic complete remission (CR) or for a maximum of 60 days. Patients in this group who achieved a CR during induction received four 8-week cycles of consolidation treatment with arsenic trioxide 0.15 mg/kg intravenously once daily for 5 days every week during weeks 1 to 4 of the 8-week cycle, in combination with tretinoin 22.5 mg/m2 (rounded to the nearest 10 mg increment) orally twice daily during weeks 1 to 2 and 5 to 6 of the 8-week cycle. Tretinoin was omitted during weeks 5 to 6 of the last cycle.</paragraph>
                        <paragraph>Patients in the chemotherapy/tretinoin group received idarubicin 12 mg/m2 intravenously once daily on days 2, 4, 6 and 8 in combination with tretinoin 22.5 mg/m2 (rounded to the nearest 10 mg increment) orally twice daily, starting on day 1, until hematologic CR or for a maximum of 60 days. Patients in this group who achieved a CR during induction received consolidation and maintenance treatment with tretinoin in combination with chemotherapy.</paragraph>
                        <paragraph>The trial enrolled 162 patients with a morphologic diagnosis of APL. The median age of patients was 45 years in the arsenic trioxide /tretinoin arm and 47 years in the chemotherapy/tretinoin arm, and 52% and 46% were male in the arsenic trioxide /tretinoin and chemotherapy/tretinoin arms, respectively. Baseline characteristics were balanced between treatment arms, including median WBC count, platelet count, PML RARA isoform, and FLT3-ITD status.</paragraph>
                        <paragraph>Efficacy was based on event-free survival (EFS) rate at 2 years. EFS was defined as the time from randomization to the occurrence of treatment failure, defined as no achievement of CR or CRi after induction therapy, no achievement of molecular remission after 3 consolidation courses, molecular relapse, hematologic relapse, or death. The primary analysis of EFS was based on the difference between the two treatment arms in patients achieving EFS at 2 years. With a median follow-up of 34.4 months, the 2 year EFS rate of the modified ITT (mITT) population (patients who received at least one dose of the assigned treatment) was 94% in the arsenic trioxide /tretinoin arm (n=77) versus 82% in the chemotherapy/tretinoin arm (n=79), a treatment difference of 11% (95% CI: 1, 22; p value 0.048). Overall survival (OS) for the mITT population was 99% (95% CI: 93, 100) in the arsenic trioxide /tretinoin arm versus 91% (95% CI: 86, 97) in the chemotherapy/tretinoin arm. The difference in 2-year OS rate between the arms was 8% (95% CI: 0, 16).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Event-Free Survival for Newly-Diagnosed APL</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                        <paragraph ID="ID691">The number of patients in the plot is based on the mITT population.</paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <section ID="ID658">
                     <id root="67058dcc-646d-4b20-ac9d-8d7e1e58b31e"/>
                     <title>14.2 Relapsed or Refractory APL</title>
                     <text>
                        <paragraph ID="ID659">Arsenic trioxide was investigated in Study PLRXAS01, an open-label, single-arm trial in 40 patients with relapsed or refractory APL who were previously treated with an anthracycline and a retinoid regimen. Patients received arsenic trioxide 0.15 mg/kg/day intravenously over 1 to 2 hours until the bone marrow was cleared of leukemic cells or for a maximum of 60 days. The CR (absence of visible leukemic cells in bone marrow and peripheral recovery of platelets and white blood cells with a confirmatory bone marrow ≥ 30 days later) rate in this population of previously treated patients was 28 of 40 (70%). Among the 22 patients who had relapsed less than one year after treatment with tretinoin, there were 18 complete responders (82%). Of the 18 patients receiving arsenic trioxide ≥ one year from tretinoin treatment, there were 10 complete responders (55%). The median time to bone marrow remission was 44 days and to onset of CR was 53 days. Three of 5 children, 5 years or older, achieved CR. No children less than 5 years old were treated.</paragraph>
                        <paragraph>Three to six weeks following bone marrow remission, 31 patients received consolidation therapy with arsenic trioxide, at the same dose, for 25 additional days over a period up to 5 weeks. In follow-up treatment, 18 patients received further arsenic trioxide as a maintenance course. Fifteen patients had bone marrow transplants. At last follow-up, 27 of 40 patients were alive with a median follow-up time of 484 days (range 280 to 755) and 23 of 40 patients remained in complete response with a median follow-up time of 483 days (range 280 to 755).</paragraph>
                        <paragraph>Cytogenetic conversion to no detection of the APL chromosome rearrangement was observed in 24 of 28 (86%) patients who met the response criteria defined above, in 5 of 5 (100%) patients who met some, but not all, of the response criteria, and 3 of 7 (43%) of patients who did not respond. RT-PCR conversions to no detection of the APL gene rearrangement were demonstrated in 22 of 28 (79%) of patients who met the response criteria, in 3 of 5 (60%) of patients who met some, but not all, of the response criteria, and in 2 of 7 (29%) of patients who did not respond.</paragraph>
                        <paragraph>Responses were seen across all age groups tested, ranging from 6 to 72 years. The ability to achieve a CR was similar for both sexes. There were insufficient patients of Black, Hispanic, or Asian ancestry to estimate relative response rates in these groups, but responses were seen in each group. </paragraph>
                     </text>
                     <effectiveTime value="20250512"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>fig.1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="db2757aa-d8c7-4114-b4bb-5eeec0df762f-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID660">
               <id root="4dbd1083-5106-43c7-8d48-1b5a325005b8"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph ID="ID661">1.         "OSHA Hazardous Drugs." OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html</paragraph>
               </text>
               <effectiveTime value="20230225"/>
            </section>
         </component>
         <component>
            <section ID="ID662">
               <id root="4d99cd71-208a-45f5-b5db-1ec8cf4aba86"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID663">
                     <content styleCode="bold">How Supplied</content>
                  </paragraph>
                  <paragraph>Arsenic trioxide injection is supplied as a sterile, clear, colorless solution in 10 mL glass, single-dose vials.</paragraph>
                  <table ID="ID664" width="91%" styleCode="Noautorules">
                     <col width="25%"/>
                     <col width="49%"/>
                     <col width="24%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> NDC</content>
                              <br/>
                           </td>
                           <td styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Strength</content>
                              <br/>
                           </td>
                           <td styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Pack Style</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="center"> 70710-1895-6<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="center"> 10 mg per 10 mL single-dose vials<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="center"> 10 vials per carton<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID665">
                     <content styleCode="bold">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Do not freeze.</paragraph>
                  <paragraph>Arsenic trioxide is a hazardous drug. Follow applicable special handling and disposal procedures.<sup>1</sup>
                  </paragraph>
               </text>
               <effectiveTime value="20230225"/>
            </section>
         </component>
         <component>
            <section ID="ID666">
               <id root="57f4d934-5fc9-4cd1-9f09-b3e713ad54ea"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID667">
                     <content styleCode="bold">Differentiation Syndrome</content>
                  </paragraph>
                  <paragraph>Advise patients that symptoms of APL differentiation syndrome include fever, sudden weight gain, dizziness/lightheadedness, labored breathing, and accumulation of fluid in the lungs, heart, and chest. This syndrome is managed by immediate treatment with high-dose corticosteroids. Advise patients to immediately report any of these symptoms <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID597">5.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cardiac Conduction Abnormalities</content>
                  </paragraph>
                  <paragraph>Advise patients that arsenic trioxide may cause ECG abnormalities, including QT prolongation. If extreme, this prolongation has the potential to cause fainting, irregular heartbeat, or more serious side effects. Advise patients to immediately report any of these symptoms. Advise patients to provide a complete list of current medications as caution should be taken when arsenic trioxide is coadministered with other medications that can cause QT prolongation or lead to electrolyte abnormalities <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID599">5.2</linkHtml>) and Drug Interactions (<linkHtml href="#ID622">7</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Encephalopathy and Wernicke's Encephalopathy (WE)</content>
                  </paragraph>
                  <paragraph>Advise patients that symptoms of encephalopathies include neurological symptoms such as confusion, decreased level of consciousness, seizures, cognitive deficits, ataxia, visual symptoms and ocular motor dysfunction. Advise patients and caregivers to closely monitor for neurological symptoms and immediately report them to their healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID601">5.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>Advise patients at risk for thiamine deficiency (e.g., chronic alcohol use, malabsorption, nutritional deficiency, concomitant use of furosemide) that Wernicke's encephalopathy is a neurologic emergency that can be prevented and treated with thiamine supplementation, and to immediately report any neurological symptoms to their healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID601">5.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID605">5.5</linkHtml>) and Use in Specific Populations (<linkHtml href="#ID625">8.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>Advise females of reproductive potential to use effective contraception during treatment with arsenic trioxide and for 6 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID629">8.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with arsenic trioxide for 3 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID629">8.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lactation </content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with arsenic trioxide and for 2 weeks after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID627">8.2</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Infertility</content>
                  </paragraph>
                  <paragraph>Advise males of reproductive potential that arsenic trioxide may impair fertility <content styleCode="italics">[see Use in Specific Population (<linkHtml href="#ID629">8.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Other Adverse Reactions </content>
                  </paragraph>
                  <paragraph>Advise patients of the expected adverse reactions of arsenic trioxide. Most patients in clinical trials experienced some drug-related toxicity, most commonly leukocytosis, gastrointestinal symptoms (nausea, vomiting, diarrhea, and abdominal pain), fatigue, edema, hyperglycemia, dyspnea, cough, rash or itching, headaches, and dizziness. Advise patients to call their healthcare provider at the onset of any adverse reactions <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID614">6.1</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250512"/>
            </section>
         </component>
         <component>
            <section ID="ID668">
               <id root="9f7eee3c-c2d7-48ca-8ce4-595a2e760060"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID669">
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Zydus Lifesciences Ltd.</content>
                  </paragraph>
                  <paragraph>Ahmedabad, India</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Zydus Pharmaceuticals (USA) Inc.</content>
                  </paragraph>
                  <paragraph>Pennington, NJ 08534</paragraph>
                  <paragraph>Rev.: 03/25</paragraph>
                  <paragraph>Novaplus is a registered trademark of Vizient, Inc.</paragraph>
               </text>
               <effectiveTime value="20250512"/>
            </section>
         </component>
         <component>
            <section ID="ID670">
               <id root="e3c46f55-3f18-4c86-b554-b0f7a97ae14f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID671">
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 70710-1895-1</paragraph>
                  <paragraph>Arsenic Trioxide Injection</paragraph>
                  <paragraph>10 mg/10 mL</paragraph>
                  <paragraph>(1 mg/mL)</paragraph>
                  <paragraph>NEW CONCENTRATION</paragraph>
                  <paragraph>For Intravenous Use Only</paragraph>
                  <paragraph>Cytotoxic Agent</paragraph>
                  <paragraph>10 mL Single-Dose Vial</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph ID="ID673">
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - Carton Label</content>
                  </paragraph>
                  <paragraph>NDC 70710-1895-6</paragraph>
                  <paragraph>Arsenic Trioxide Injection</paragraph>
                  <paragraph>10 mg/10 mL</paragraph>
                  <paragraph>(1 mg/mL)</paragraph>
                  <paragraph>NEW CONCENTRATION</paragraph>
                  <paragraph>For Intravenous Use Only</paragraph>
                  <paragraph>10 X 10 mL Single-Dose Vials</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20250512"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>arsenic trioxide injection, 1 mg/mL-Vial label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="db2757aa-d8c7-4114-b4bb-5eeec0df762f-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Arsenic trioxide Injection 1 mg/mL-carton label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="db2757aa-d8c7-4114-b4bb-5eeec0df762f-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>